Synthetic cannabinoid receptor agonists in oral fluid: development of a dispersive liquid–liquid microextraction method with liquid chromatography–mass spectrometry detection
Journal of Analytical Toxicology · 2025
DOI: 10.1093/jat/bkaf027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Analytical Toxicology, 2025. Verfasst von Henrique Silva Bombana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo 01246-903, Brazil. Hauptthemen laut MEDLINE: Liquid Phase Microextraction, Saliva, Cannabinoid Receptor Agonists, Substance Abuse Detection. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de Sào Paulo, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Synthetic cannabinoid receptor agonists (SCRA) comprise a class of new psychoactive substances (NPS) that rank second in terms of notified substances to the United Nations Office on Drugs and Crime. Moreover, SCRA are the most prevalent NPS in Brazilian territory. Given the risks they pose to public health, there is a pressing need to develop simple and rapid sample preparation methods in alternative biological matrices that are easy to handle and collect, such as oral fluid (OF). In this study, dispersive liquid–liquid microextraction was employed to determine 12 SCRAs in OF. For 200 µl of the sample (mixture of OF and Quantisal™ buffer), 200 µl of ice-cold acetonitrile was used as the dispersive solvent, and 100 µl of ethyl acetate was used as the extraction solvent. The limits of detection ranged from 0.5 to 2 ng/mL, while the limits of quantification were 2 ng/mL for ADB-FUBIATA and 1 ng/mL for the other analytes. The working range was 1–100 ng/mL, except for ADB-FUBIATA, which had a range of 2–100 ng/mL. The coefficients of variation for quantified analytes were <11.3% for within-run precision, <12.6% for between-run precision, and <15.8% for accuracy across all controls. The developed method was applied to six suspected samples, and one sample yielded a positive result with 39.9 ng/mL of MDMB-4en-PINACA, the most prevalent SCRA in São Paulo State, Brazil.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo 01246-903, Brazil.
- Departamento de Medicina Legal, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP 05508-000, Brazil.
ORCID-Profile: Henrique Silva Bombana, Gabriela de Paula Meirelles, Rodrigo Alves de Oliveira, Vilma Leyton, Mauricio Yonamine
Förderung
- Fundação de Amparo à Pesquisa do Estado de Sào Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Bombana, H. S., de Paula Meirelles, G., de Oliveira, R. A., Leyton, V., & Yonamine, M. (2025). Synthetic cannabinoid receptor agonists in oral fluid: development of a dispersive liquid–liquid microextraction method with liquid chromatography–mass spectrometry detection. Journal of Analytical Toxicology. https://doi.org/10.1093/jat/bkaf027
Vancouver
Bombana HS, de Paula Meirelles G, de Oliveira RA, Leyton V, Yonamine M. Synthetic cannabinoid receptor agonists in oral fluid: development of a dispersive liquid–liquid microextraction method with liquid chromatography–mass spectrometry detection. Journal of Analytical Toxicology. 2025. doi:10.1093/jat/bkaf027
BibTeX
@article{Bombana2025,
author = {Bombana, Henrique Silva and de Paula Meirelles, Gabriela and de Oliveira, Rodrigo Alves and Leyton, Vilma and Yonamine, Mauricio},
title = {Synthetic cannabinoid receptor agonists in oral fluid: development of a dispersive liquid–liquid microextraction method with liquid chromatography–mass spectrometry detection},
journal = {Journal of Analytical Toxicology},
year = {2025},
doi = {10.1093/jat/bkaf027}
}
EUVIMED